See leaflet
See Risk Management Plan
Ibruleu®
ibrutinib
Indications
- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion
- Mantle cell lymphoma (MCL) who have received at least one prior treatment
- Waldenström’s macroglobulinemia (WM)
- Marginal zone lymphoma (MZL)
Presentations
- 140 mg x 90 capsules
- 140 mg x 120 capsules
- 140 mg x 90 capsules
- 140 mg x 120 capsules